Health & Environmental Research Online (HERO)


Print Feedback Export to File
6775837 
Journal Article 
Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomised controlled trial 
Palui, R; Sahoo, J; Kamalanathan, S; Kar, SS; Sridharan, K; Durgia, H; Raj, H; Patil, M 
2019 
Yes 
Journal of Endocrinological Investigation
ISSN: 0391-4097
EISSN: 1720-8386 
42 
12 
1451-1458 
English 
31127593 
WOS:000494824400006 
PURPOSE: Though most of the observational studies have shown that metformin can reduce serum thyroid stimulating hormone (TSH) level in patients of hypothyroidism with diabetes or polycystic ovarian disease, randomised controlled trials are sparse. The primary objective of this study was to evaluate the effect of metformin on thyroid function tests (TSH, free T4, and free T3) in patients with subclinical hypothyroidism (SCH).

METHODOLOGY: In this open label, parallel arm, randomised controlled trial, 60 patients of SCH (TSH 5.5-10 mIU/L) were randomised to either metformin group (1500 mg/day) or control group.

RESULT: A total of 46 patients (23 in each group) completed the study and no significant difference in serum TSH, free T4 or free T3 was found in between the 2 groups. Neither there was any significant change in serum TSH, free T4 or free T3 (pre and post 6 months) within the individual groups. However, the rate of normalisation of serum TSH in patients with negative thyroid antibody was significantly higher than patients with positive thyroid antibody (71.4% vs. 18.8%; P = 0.026) in metformin group in post hoc analysis. Fasting plasma glucose, serum high-density lipoprotein and indices of insulin sensitivity significantly improved in metformin group. Four patients (17%) had mild gastrointestinal adverse effects in the metformin group.

CONCLUSION: We did not find any significant change in thyroid function test in patients with SCH with metformin therapy.